Expert Profile
Industrial neuropharmacologist with two decades of proven achievement in drug discovery of novel antipsychotics, antidepressants and analgesics. Expertise in serotonin receptor pharmacology.
Extensive management experience of multidisciplinary pharmacology research. Leadership of project teams including medicinal chemists, early ADMET and preclinical development partners. Collaborations with academic researchers and Due Diligence / licensing discussions.
Numerous publications (>130) in peer-reviewed journals and multiple symposia presentations to diverse audiences.
Bi-national: British, Italian. Tri-lingual: English, French, Italian.
Consultant at NeuroAct Communication.
Chief Scientific Officer: Neurolixis Inc.
Therapeutic areas: psychopharmacology (antipsychotics, antidepressants), chronic pain (fibromyalgia), neurology (antiparkinson)...
Director, Psychopharmacology Division,
Pierre Fabre Laboratories, *****.
Management of 20 FTEs and dotted-line management of a further dozen FTEs in other departments. Multidisciplinary structure covering molecular, neurochemical and behavioural pharmacology.
.
Research Scientist, Psychopharmacology Division,
Servier Research Institute, *****
In vitro molecular pharmacology of monoamine receptors and transporters. Management of 5-6 FTEs.
University of Kent at Canterbury, UK
Ph.D. *****
University of Kent at Canterbury, UK
B.Sc. *****
College of International NeuroPsychopharmacology (CINP)
British Pharmacological Society (BPS)
American Society for Neuroscience (SfN)
Serotonin Club
Expertise in neuropharmacology and preclinical drug discovery (over 130 peer-reviewed publications). Defining target selection and validation criteria. Project management, building experimental flow charts, candidate profiling.